NVS

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Novartis AG - ADR

CEO
Employees
105794
Headquarters

Lichtstrasse 35
Basel, Basel Stadt 4056
Phone: 41613241111
https://www.novartis.com/

News

Novartis And Medicines For Malaria Venture Reports Positive Data From Phase II/III CALINA Study
Apr 24, 2024 06:06am

BASEL (dpa-AFX) - Novartis AG (NVS) and Medicines for Malaria Venture Wednesday said results from the phase II/III CALINA study showed the novel formulation of Coartem to treat babies weighing les…


Source:Finanz Nachrichten
Novartis Pharma AG: Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Apr 24, 2024 04:34am

There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic diff…


Source:Finanz Nachrichten
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Apr 24, 2024 04:30am

Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem ® (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and good efficacy and safety. The trial was conducted in several African countries. The data, which will be presented this week at the Multilateral Initiative on Malaria (MIM Society) 8th Pan-African Malaria Conference in Kigali, have been submitted for regulatory review.


Source:GlobeNewswire
FDA Approves Novartis'' Lutathera For Pediatric Gastroenteropancreatic Neuroendocrine Tumors
Apr 24, 2024 03:24am

BASEL (dpa-AFX) - Novartis (NVS) said that the U.S. Food and Drug Administration approved Lutathera for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive g…


Source:Finanz Nachrichten
Novartis Surges After Forecast Boost Beats Expectations
Apr 24, 2024 03:00am

V nadaljevanju: Novartis AG raised its forecast as sales of blockbuster medicines for heart disease and psoriasis outpaced expectations, giving the stock its biggest boost in nine months.Sales will grow at a… Za dostop registrirajte uporabniško ime ali pa se prijavite, če ime že imate.


Source:TIMES.si
Novartis wins pediatric indication for Lutathera for rare cancer
Apr 23, 2024 18:08pm

No summary available.


Source:Seeking Alpha
Novartis stock target raised to $108 on improved guidance
Apr 23, 2024 18:03pm

https://www.investing.com/news/company-news/novartis-stock-target-raised-to-108-on-improved-guidance-93CH-3391688


Source:Investing.com
Novartis Pharma AG: Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Apr 23, 2024 17:58pm

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic ne…


Source:Finanz Nachrichten
Novartis radioligand therapy Lutathera FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Apr 23, 2024 17:42pm

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of disease Novartis, a leader in radioligand therapy (RLT), Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Watch CNBC''s full interview with Novartis CEO Vas Narasimhan on earnings and weight loss drugs
Apr 23, 2024 17:15pm

Vas Narasimhan, Novartis CEO, joins ''Money Movers'' to discuss what feeds the company''s strong guidance, if pricing in the U.S. will involve some friction, and more.


Source:CNBC